A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Myasthenia Gravis Clinical Trial

Official title:

An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05265273
• Other study ID #: CR109137
• Secondary ID: 2021-002479-2080
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: July 20, 2022
• Est. completion date: December 30, 2025

Study information

• Verified date: June 2024
• Source: Janssen Research & Development, LLC
• Contact: Study Contact
• Phone: 844-434-4210
• Email: Participate-In-This-Study[@]its.jnj.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (<) 18 years of age (globally) and 8 to <18 years of age (for Unites Stated (US) sites only), the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing, stable standard-of-care therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: December 30, 2025
• Est. primary completion date: March 19, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 17 Years

Eligibility

Inclusion Criteria:

• Age: For US sites only: 8 to <18 years
• Diagnosis of myasthenia gravis (MG) with generalized muscle weakness meeting the clinical criteria for generalized myasthenia gravis (gMG) as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class IIa/b, IIIa/b, or IVa/b at screening
• Has a positive serologic test for acetylcholine receptor (anti-AChR) antibodies or muscle-specific tyrosine kinase (anti-MuSK) antibodies at screening
• A participant using herbal, naturopathic, traditional Chinese remedies, ayurvedic or nutritional supplements, or medical marijuana (with a doctor's prescription) is eligible if the use of these medications is acceptable to the Investigator. These remedies must remain at a stable dose and regimen throughout the study
• Has sufficient venous access to allow drug administration by infusion and blood sampling as per the protocol
• Participants should have a body weight and body mass index between 5th and 95th percentile for age and sex. Obese participants greater than 95th percentile and underweight participants below 5th percentile may participate following medical clearance
• A female of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine pregnancy test at Day 1 prior to administration of study intervention

Exclusion Criteria:

• Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/ autoimmune hepatitis/ cirrhosis/ and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular (including congenital heart diseases), psychiatric, neurological musculoskeletal disorder, any other medical disorder(s) (example, diabetes mellitus), or clinically significant abnormalities in screening laboratory, that might interfere with participant's full participation in the study, and/ or might jeopardize the safety of the participant or the validity of the study results
• Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her generalized myasthenia gravis (gMG), or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
• Has had a thymectomy within 12 months prior to screening, or thymectomy is planned during the Active treatment Phase of the study
• Has shown a previous severe immediate hypersensitivity reaction, such as anaphylaxis to therapeutic proteins (example, monoclonal antibodies)
• Has experienced myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks of screening

Related Conditions & MeSH terms

• Muscle Weakness
• Myasthenia Gravis

Intervention

Drug:
• Nipocalimab
Nipocalimab will be administered as an IV infusion.

Locations

Country	Name	City	State
Japan	Nagano Children's Hospital	Azumino-shi, Nagano
Japan	Chiba University Hospital	Chiba
Japan	University of Miyazaki Hospital	Miyazaki
Japan	Hyogo College of Medicine Hospital	Nishinomiya-Shi
Japan	Saitama Prefecture Children's Medical Center	Saitama shi
Japan	Tokyo Women's Medical University Hospital	Shinjuku-ku
Netherlands	Leiden University Medical Center	Leiden
Poland	Uniwersyteckie Centrum Kliniczne	Gdansk
United States	C.S. Mott Children's Hospital	Ann Arbor	Michigan
United States	Children's Hospital Colorado	Aurora	Colorado
United States	University of Kansas Medical Center	Lawrence	Kansas
United States	Childrens Hospital Los Angeles	Los Angeles	California
United States	Lucile Packard Children's Hospital Stanford	Palo Alto	California
United States	Childrens Hospital Of Philadelphia	Philadelphia	Pennsylvania
United States	Phoenix Children's Hospital	Phoenix	Arizona
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	UCSF Benioff Children's Hospital	San Francisco	California
United States	University of South Florida Morsani Center for Advanced Healthcare	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Research & Development, LLC

Countries where clinical trial is conducted

United States,  Japan,  Netherlands,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Total Serum Immunoglobulin-G (IgG) Antibodies Levels	Change from baseline in total serum IgG antibodies levels were reported.	Up to 3 years
Primary	Number of Participants with Infectious Adverse Events (AEs)	Number of participants with infectious AEs will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.	Up to 3 years
Primary	Number of Participants with Serious AEs (SAEs)	Number of participants with SAEs will be reported. A SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect, is suspected transmission of any infectious agent via a medicinal product, is medically important to prevent one of the outcomes listed above.	Up to 3 years
Primary	Number of Participants with Adverse Events of Special Interests (AESIs)	Number of participants with AESIs will be reported. Treatment-emergent AEs associated with the following situations are considered an AESI: a) infections that are severe or require intravenous (IV) anti-infective or operative/invasive intervention; b) hypoalbuminemia with albumin less than (<)20 grams per liter (g/L) [<] 2.0 grams per deciliter [g/dL]) and c) opportunistic infections. Any AE occurring at or after the initial administration of study intervention through end of study is treatment emergent.	Up to 3 years
Primary	Number of Participants with Abnormalities in Clinical Laboratory Tests	Number of participants with abnormalities in clinical laboratory tests (including chemistry, hematology, coagulation, and urinalysis) will be reported.	Up to 3 years
Primary	Number of Participants with Abnormalities in Vital Signs	Number of participants with abnormalities in vital signs including sitting pulse/heart rate, sitting systolic and diastolic blood pressure, and oral temperature (degrees Celsius) will be reported.	Up to 3 years
Primary	Number of Participants with Abnormalities in Physical Examination	Number of participants with abnormalities in physical examinations including height, weight, assessments of the skin, head, eyes, ears, nose, throat, neck, thyroid, lungs, heart, abdomen, lymph nodes and extremities will be reported.	Up to 3 years
Primary	Serum Concentration of Nipocalimab over Time	Serum samples will be analyzed to determine concentrations of nipocalimab using a validated, specific, and sensitive immunoassay method.	Up to 3 years
Primary	Clearance (CL) of Nipocalimab	CL is defined as the volume of serum from which nipocalimab is completely removed per unit time.	Up to 3 years
Primary	Volume of Distribution (V) of Nipocalimab	V is defined as the representation of nipocalimab's propensity to either remain in the serum or redistribute to other tissue compartments.	Up to 3 years
Primary	Half-life (t1/2) of Nipocalimab	t1/2 is defined as the time it takes for nipocalimab's active substance in the body to reduce by half.	Up to 3 years
Primary	Steady-state Peak Concentration (Cpeak,ss) of Nipocalimab	Cpeak,ss is defined as the peak serum concentration of nipocalimab at steady state.	Up to 3 years
Primary	Steady-state Trough concentration (Ctrough,ss) of Nipocalimab	Ctrough,ss will be reported. It is defined as the observed serum concentration of nipocalimab just prior to the beginning of a dosing interval at steady state.	Up to 3 years
Primary	Steady-state Area Under the Curve (AUCss) of Nipocalimab	AUCss is defined as the area under the curve for nipocalimab at steady state.	Up to 3 years
Secondary	Change from Baseline in Myasthenia Gravis -Activities of Daily Living (MG-ADL) Score	Change from baseline in MG-ADL score will be reported. The MG-ADL score provides a rapid assessment of the participant's myasthenia gravis (MG) symptom severity. Eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, eyelid droop) are rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score will be sum of eight function scores and can range from 0 to 24. A higher score indicates greater symptom severity.	Up to 3 years
Secondary	Change in the Quantitative Myasthenia Gravis (QMG) Score	The QMG score is a standardized quantitative strength assessment comprising 13 components (and is administered by a trained qualified healthcare professional [HCP] eg, physician, physician assistant, nurse practitioner, nurse). The quantitative results of each strength component are mapped to the following 4-point scale: 0 equals to (=) none, 1 = mild, 2 = moderate and 3 = severe. The total score will be sum of 13 components scores and can range from 0 to 39. A higher score indicates greater weakness.	Up to 3 years
Secondary	European Quality of Life 5-Dimension Youth (EQ-5D-Y) Tool Score	The EQ-5D-Y is a standardized child friendly instrument for use as a measure of health status, primarily designed for self-completion by children and adolescents, or via a proxy version to be completed by the child's caregiver. The EQ-5D-Y descriptive system comprises the following 5 dimensions: Mobility, looking after myself (washing and dressing), usual activities, pain or discomfort and feeling worried or unhappy. Each of the 5 dimensions is divided into 3 levels of perceived problems (Level 1 indicating no problem, Level 2 indicating some problems, Level 3 a lot of problems).	Up to 3 years
Secondary	Neurological Quality of Life (Neuro-QoL) Pediatric Fatigue Score	The Neuro-QoL pediatric fatigue score will be used to assess the impact of fatigue in participants aged 10 to less than (<) 18 years. The participant will rate each of the 11 items on a 5-point scale. Higher scores indicate greater fatigue.	Up to 3 years
Secondary	Patient Global Impression of Severity (PGI-S) Score	The PGI-S score will be used to assess the severity of fatigue due to generalized myasthenia gravis (gMG) in participants aged 10 to < 18 years. Participants will be asked to rate their fatigue over the past 7 days using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe. Higher scores indicate greater severity of fatigue.	Up to 3 years
Secondary	Patient Global Impression of Change (PGI-C) Score	The PGI-C score will be used to assess if there has been an improvement or decline in patient-reported fatigue since the beginning of the treatment in participants aged 10 to <18 years. Participants will be asked to rate their current fatigue as compared to when they started the study, using the following 7-point scale: 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, and 7 = Much worse. Higher scores indicate greater change in overall fatigue.	Up to 3 years
Secondary	Number of Participants with Anti-Drug Antibodies [ADAs] to Nipocalimab	Number of participants with ADAs to nipocalimab will be reported.	Up to 3 years
Secondary	Number of Participants with Neutralizing Antibodies (NAbs) to Nipocalimab	Number of participants with NAbs to nipocalimab will be reported.	Up to 3 years
Secondary	Number of Participants with Vaccine Antibody Titers to Diphtheria or Tetanus	Number of participants with vaccine antibody titers to diphtheria or tetanus will be reported.	Up to 3 years